- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Focus nets clearance for CardioMatch
Focus Medical has received Food and Drug Administration 510(k) clearance for CardioMatch, a 3-D image analysis software program designed to improve the specificity of a myocardial perfusion study. The Belmont, CA-based company is also in final
Focus Medical has received Food and Drug Administration 510(k) clearance for CardioMatch, a 3-D image analysis software program designed to improve the specificity of a myocardial perfusion study. The Belmont, CA-based company is also in final negotiations with a major medical university and hospital group in Northern California to perform a large clinical validation study using CardioMatch.
CardioMatch has been cleared as a cardiac diagnostic software program to quantitatively analyze myocardial perfusion in patients injected with Cardiolite or thallium-201 following a rest/stress SPECT acquisition protocol. The company unveiled CardioMatch at the annual meeting of the Society of Nuclear Medicine in June (SCAN Special Report 6/97).
Focus plans to continue to pursue new applications for its image analysis technology. The firm expects to file a 510(k) application in the fourth quarter for PneumoMatch, which is targeted at the early detection, quantitation, and 3-D visualization of pulmonary embolism. Additional neurological and oncologic applications are also on the drawing board.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
